103 related articles for article (PubMed ID: 8680074)
1. [Contribution of computers to pharmacokinetics, Bayesian approach and population pharmacokinetics].
Hecquet B
Bull Cancer; 1995 Dec; 82 Suppl 5():607s-611s. PubMed ID: 8680074
[TBL] [Abstract][Full Text] [Related]
2. Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package.
Gomeni R; Pineau G; Mentré F
Anticancer Res; 1994; 14(6A):2321-6. PubMed ID: 7825966
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic variability of nimodipine disposition after single and multiple oral dosing to hypertensive renal failure patients: parametric and nonparametric population analysis.
Terziivanov D; Atanasova I; Dimitrova V; Robeva R; Unger S; Mück W
Int J Clin Pharmacol Ther; 1999 Aug; 37(8):404-12. PubMed ID: 10475143
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of heated intraperitoneal oxaliplatin.
Ferron G; Dattez S; Gladieff L; Delord JP; Pierre S; Lafont T; Lochon I; Chatelut E
Cancer Chemother Pharmacol; 2008 Sep; 62(4):679-83. PubMed ID: 18084764
[TBL] [Abstract][Full Text] [Related]
5. Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage.
Bondareva IB; Jelliffe RW; Sokolov AV; Tischenkova IF
J Clin Pharm Ther; 2004 Apr; 29(2):105-20. PubMed ID: 15068399
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients.
Latz JE; Chaudhary A; Ghosh A; Johnson RD
Cancer Chemother Pharmacol; 2006 Apr; 57(4):401-11. PubMed ID: 16322991
[TBL] [Abstract][Full Text] [Related]
7. [Bayesian estimation of pharmacokinetic parameters of etoposide].
Evene E; Chatelut E; Tranchand B; Canal P; Lochon I; Iliadis A; Ardiet CJ
Bull Cancer; 1997 Jul; 84(7):699-703. PubMed ID: 9339195
[TBL] [Abstract][Full Text] [Related]
8. [Application of population pharmacokinetic approach to clinical evaluation of anticancer agents].
Tanigawara Y
Gan To Kagaku Ryoho; 2001 May; 28(5):711-21. PubMed ID: 11383224
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy.
Panteix G; Beaujard A; Garbit F; Chaduiron-Faye C; Guillaumont M; Gilly F; Baltassat P; Bressolle F
Anticancer Res; 2002; 22(2B):1329-36. PubMed ID: 12168946
[TBL] [Abstract][Full Text] [Related]
10. A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia.
Plard C; Bressolle F; Fakhoury M; Zhang D; Yacouben K; Rieutord A; Jacqz-Aigrain E
Cancer Chemother Pharmacol; 2007 Sep; 60(4):609-20. PubMed ID: 17195068
[TBL] [Abstract][Full Text] [Related]
11. [Validation of a new interactive software monitoring a controlled-flow infusion pump for cisplatin dosage regimen adjustment].
Cupissol D; Brès J; Gestin-Boyer C; Nouguier-Soulé J; Vian L; Tep A; Nouguier J
Bull Cancer; 1996 Aug; 83(8):664-76. PubMed ID: 8869047
[TBL] [Abstract][Full Text] [Related]
12. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control.
Jelliffe RW; Schumitzky A; Van Guilder M; Liu M; Hu L; Maire P; Gomis P; Barbaut X; Tahani B
Ther Drug Monit; 1993 Oct; 15(5):380-93. PubMed ID: 8249044
[TBL] [Abstract][Full Text] [Related]
13. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
14. [Can we use a Bayesian method to build a pharmacokinetic population in two steps?].
Cabelguenne D; Bleyzac N; Pivot C; Maire P
Therapie; 2000; 55(2):277-82. PubMed ID: 10967700
[TBL] [Abstract][Full Text] [Related]
15. Bayesian calculation of methotrexate clearance after low dose intramuscular administration in patients with rheumatoid arthritis.
Monjanel-Mouterde S; Lafforgue P; Blanc A; Catalin J; Aquaviva PC; Durand A
J Rheumatol; 1998 Jul; 25(7):1276-81. PubMed ID: 9676756
[TBL] [Abstract][Full Text] [Related]
16. [The benefits of computerized anticancer drug distribution].
Chast F; Brandely ML; Bardin C
Bull Acad Natl Med; 2005 Nov; 189(8):1721-32; discussion 1732-3. PubMed ID: 16737097
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Bayesian approach and a limited sampling model for the estimation of AUC and Cmax: a computer simulation analysis.
Mahmood I; Miller R
Int J Clin Pharmacol Ther; 1999 Sep; 37(9):439-45. PubMed ID: 10507242
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data.
Fukuhara K; Ikawa K; Morikawa N; Kumagai K
J Clin Pharm Ther; 2008 Dec; 33(6):677-84. PubMed ID: 19138246
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
Blair EY; Rivory LP; Clarke SJ; McLachlan AJ
Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
[TBL] [Abstract][Full Text] [Related]
20. A Bayesian population PK-PD model of ispinesib-induced myelosuppression.
Kathman SJ; Williams DH; Hodge JP; Dar M
Clin Pharmacol Ther; 2007 Jan; 81(1):88-94. PubMed ID: 17186004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
